Nplate Produces Rapid Response in Adults with ITP

Among adults with low platelet counts or bleeding symptoms from primary immune thrombocytopenia (ITP), treatment with Nplate® (romiplostim) produces a rapid increase in platelet counts. These results were presented at the 53rd Annual Meeting of the American Society of Hematology.

Thrombocytopenia occurs when platelet levels fall below normal. It can often occur as a direct result of cancer, from cancer treatment, or from other diseases such as ITP. Adult chronic ITP is an autoimmune disorder in which the patient’s immune system attacks mature platelets or attacks the cells in the body that produce platelets. This results in thrombocytopenia and puts the patient at risk of serious bleeding problems.

Nplate is an agent that stimulates the production of platelets in the bone marrow. Nplate has been approved for the treatment of thrombocytopenia in adult ITP patients who have not responded to standard therapies and is also being evaluated in the management of other patients with thrombocytopenia.

The current study involved more than 400 ITP patients, all of whom had received prior treatment for ITP. Study participants were treated with Nplate once per week.

  • The most common side effects of Nplate included headache, joint pain, and fatigue.
  • 91 percent of patients had a doubling of their platelet count to at least 50,000 platelets per microliter.
  • The median time required to achieve a platelet response was one to two weeks

These results continue to support the use of Nplate for adults with ITP. Nplate produced a rapid platelet response in these patients.

Reference: Janssens A, Tarantino MD, Bird R et al. Final results from an international, multi-center, single-arm study evaluating the safety and efficacy of romiplostim in adults with primary immune thrombocytopenia. Presented at the 53rd ASH Annual Meeting and Exposition. San Diego, CA, December 10-13, 2011. Abstract 3279.

Copyright © 2011 CancerConsultants. All Rights Reserved.